Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Genitourinary Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Genitourinary Disease Site Committee, the Genitourinary Disease Site Executive Committee, and the CCTG Patient Representative Committee.
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Gynecology Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gynecology Disease Site Committee, the Gynecology Disease Site Executive Committee, and the CCTG Patient Representative Committee.
The deadline is approaching to submit applications for the 2024-2025 CCTG Practicum.
The CCTG MY13 trial is a phase III non-inferiority randomized controlled trial of fixed duration versus continuous daratumumab among transplant in eligible older adults with newly diagnosed multiple myeloma.
There is little scientific evidence around the effective timing of injectable treatments for multiple myeloma. These patients receive treatment with three medicines - two tablets and an injection - all continued indefinitely until they stop working, or the side effects become unmanageable.
The Frances A Shepherd Award is for investigators or post-graduate trainees, traveling to present CCTG related work at major international meetings. Each award will be approximately $1000 and offered two to three times a year. Applicants who have had their research accepted for oral or poster presentation at an international scientific meeting and have not received another award to support their travel are eligible to apply. The application deadline will be set in the spring and fall to coincide with the major international cancer conferences.
